Wednesday, February 10, 2010, 8:35am EST - Canadian Markets open in 55 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Antigenics Inc. (AGEN)

 On Feb 9: 0.735 USD   0.00 (0.00%)  
MORE ON AGEN
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Antigenics Inc. (NCM:AGEN) Delayed quote dataEdit
Last Trade: 0.735 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 0.735
Open: N/A
Bid: 0.71 x 2100
Ask: 0.78 x 300
1y Target Est: 3.40
Day's Range: N/A - N/A
52wk Range: 0.27 - 3.34
Volume: 0
Avg Vol (3m): 912,554
Market Cap: 65.96M
P/E (ttm): N/A
EPS (ttm): -0.366
Div & Yield: N/A (N/A%)
Antigenics Inc. (AGEN)
1d  5d  3m  6m  1y  2y  5y  max 
 Add AGEN to Portfolio   Download Data

HEADLINES
• Antigenics Files $100 Million Mixed Shelf: BioBuzz
at TheStreet.com (Mon, Jan 25)
• New Gold, Poniard: Early Volume Plays
at TheStreet.com (Mon, Jan 25)
• ANTIGENICS INC /DE/ Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar
EDGAR Online (Thu, Dec 31)
• Antigenics Receives NASDAQ Delisting Notification
Business Wire (Thu, Dec 31)
• Mentor Capital Cancer Vaccine Investing Update
at Seeking Alpha (Wed, Dec 23)
• Biotech Stock Mailbag: Year in Review
at TheStreet.com (Fri, Dec 18)
• Antigenics pulls European Oncophage application
AP (Fri, Nov 20)
• ANTIGENICS INC /DE/ Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
EDGAR Online (Fri, Nov 20)
• European CHMP Formally Adopts Negative Opinion on Oncophage®
Business Wire (Fri, Nov 20)
• ANTIGENICS INC /DE/ Financials
EDGAR Online Financials (Fri, Nov 13)
• ANTIGENICS INC /DE/ Files SEC form 10-Q, Quarterly Report
EDGAR Online (Mon, Nov 9)
More Headlines for AGEN...
ANALYST
EPS Est (next year) (Dec-09) : -0.52
EPS Est (in 2 years) (Dec-10) : -0.36
Avg Rec (current)*: 3.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Antigenics Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices